Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

YNHH and MSK are founding academic members of the consortium. As pioneering institutions, they will contribute to defining the vision, governance, and strategic direction of this open-source ecosystem ...

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...

Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is ...

Tempus AI Inc. (NASDAQ:TEM) is one of the 9 Stocks Stealing the Show. Tempus AI extended its winning streak to a 3rd straight session on Wednesday, surging 13.89 percent to close at $56.41 apiece, as ...

Tempus AI’s TEM strategic focus for 2026 centers on expanding its AI-driven precision medicine platform by scaling the ...

Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines. “Staying current with rapidly evolving clinical guidelines—especially regarding biomarker ...

Tempus AI Inc TEM stock is trading higher on Thursday morning following a key product expansion announcement. The company ...

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care ...